Kinase inhibitors are central to modern therapeutics, yet early discovery often relies on assays with limited mechanistic or physiological insight—creating a disconnect between biochemical results and biological complexity. To address this limitation, we have developed continuous fluorescence-based assays that directly quantify kinase activity in crude lysates and tissue homogenates. By delivering real-time insights under more physiological conditions, these assays help identify more effective drugs earlier to improve translational success with patients.

 Would you like to have our CSO give you a presentation of how we enable real-time enzymology of kinase activity in complex cell lysate matrices?